56 194

Cited 0 times in

Novel Therapies for Type 2 Diabetes Mellitus

Other Title
2형 당뇨병의 새로운 치료
고, 정민
Annals of pediatric endocrinology & metabolism, 14(1):11-18, 2009
Journal Title
Annals of pediatric endocrinology & metabolism
Type 2 diabetes mellitus (T2DM) is a progressive disorder caused by a combination of insulin resistance and β cell dysfunction. The role of new hormones and systems in maintaining blood glucose homeostasis has recently been recognized. This recognition has led to the development of several novel classes of medications, including the incretin mimetic agents (glucagon like polypeptide-1 analogs and dipeptidyl peptidase IV inhibitors), the amylin analog and the endocannabinoid-1 receptor blocker. This review looks at these new agents in terms of their mode of action, pharmacokinetics and use in clinical practice. The new agents offer treatment options in select adult patients now, however, the efficacy and the safety has to be evaluated thoroughly by long term studies before the application to pediatric patients.
IncretinGlucagon like polypeptidesDipeptidyl peptidase IV inhibitorsAmylinEndogenous cannabinoidsDiabetes MellitusType 2
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Medical Genetics
AJOU Authors
고, 정민
Files in This Item:
fulltext not available.txtDownload
RIS (EndNote)
XLS (Excel)


해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.